News & Trends - Pharmaceuticals

MSD’s Keytruda registered for fifteenth indication in Australia – RCC

Health Industry Hub | June 22, 2020 |
[Total: 1    Average: 5/5]

Pharma News: Australians with a common form of kidney cancer, advanced renal cell carcinoma, can now count immuno-oncology therapy KEYTRUDA (pembrolizumab), as a treatment option, when combined with another cancer medicine from the selective tyrosine kinase inhibitor class.

MSD’s cancer treatment KEYTRUDA has been listed on the Australian Register of Therapeutic Goods (ARTG) for use in combination with Inlyta (axitinib), for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

This registration is the fifteenth (15th) indication for KEYTRUDA in Australia and reinforces MSD’s commitment in the area of oncology, and the importance of KEYTRUDA as a treatment option for eligible Australian cancer patients.

This latest indication for advanced renal cell carcinoma is a significant step forward for the 3,800 Australian patients that are diagnosed with this disease each year, KEYTRUDA is a cancer immunotherapy that works to reactivate the immune system to attack tumour cells by blocking a specific cancer cell protein (known as PD-1 or programmed cell death protein), which left unchecked allows cancer cells to pass undetected by the body’s natural defences.

Register-and-join-Health-Industry-Hub-Pharma-MedTech-Biotech

Renal cell carcinoma accounts for approximately 90% of all kidney cancers, and approximately one in three renal cell carcinomas are diagnosed at an advanced stage. Kidney cancer is estimated to be the ninth most commonly diagnosed cancer in Australia, and approximately 1,000 Australians die each year from this form of cancer.   

Men are almost twice as likely to develop kidney cancer than women, and risk factors include high blood pressure, smoking, obesity and a family history of kidney cancer.

Associate Professor Andrew Weickhardt, Medical Oncologist at the Olivia Newton-John Cancer Research Institute, specialises in kidney cancer “The registration of Keytruda in combination with axitinib for advanced renal cell carcinoma will provide Australian patients and clinicians with another treatment option for this difficult-to-treat cancer.

“Combining therapies together to treat cancer is becoming more common in the field of oncology. The activity of this combination means that there is another treatment available for eligible patients and provides another option for oncologists to consider in the management of their patients with RCC,” continued Associate Professor Weickhardt.

Selfcare In Healthcare Coalition on Mental Health Support in Pharma, Biotech and MedTech

MSD Managing Director for Australia and New Zealand, Mr Michael Azrak, said the 15th indication for KEYTRUDA is a significant oncology milestone.

“We are committed to bringing our immuno-oncology therapy KEYTRUDA to as many eligible Australian patients as possible. Oncology combination therapies have the potential to increase treatment options for Australian patients living with cancer.

“It is now crucial that the Australian Government works collaboratively with industry to develop and implement suitable frameworks to enable timely and affordable access to combination therapies for Australian patients,” said Mr Azrak.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Private health insurer looking to invest in Australian private hospitals

Private health insurer looking to invest in Australian private hospitals

Health Industry Hub | July 15, 2020 |

MedTech News: In a recent opinion piece Dr Bill Coote, former AMA Secretary General and former Director of the Medicare […]

More


News & Trends - Pharmaceuticals

Pharma News - Merck Australia supports the first Australian-developed COVID-19 vaccine - Sypharma and Vaxine

Merck Australia supports the first Australian-developed COVID-19 vaccine

Health Industry Hub | July 15, 2020 |

Pharma News: Sypharma, an Australian biopharmaceutical formulation company, announced manufacturing of COVAX-19 and Advax adjuvant for Covid-19 in partnership with […]

More


News & Trends - Pharmaceuticals

Pharma News - Precision prescribing to combat Australia’s expected surge in mental illness

Precision prescribing to combat Australia’s expected surge in mental illness

Health Industry Hub | July 15, 2020 |

Pharma News: COVID-19 social isolation, familial and community disconnection, shock, job loss and health fears create the perfect storm for […]

More


Medical

Medical Pharma Biotech MedTech - $47M accelerator program for MedTech, Biotech and Pharma sectors in diabetes and cardiovascular disease

$47M accelerator program for MedTech, Biotech and Pharma sectors in diabetes and cardiovascular disease

Health Industry Hub | July 15, 2020 |

Medical News: The operation of the Australian Government’s $47 million Targeted Translation Research Accelerator (TTRA) initiative for diabetes and cardiovascular […]

More